In Vitro Diagnostics Global market - Forecast to 2023

Publishing Date : May, 2017
Report Code : HCMD 0099
Price:
Single license $4,950
Site license $6,750
Global license $9,000


In-vitro diagnostic is a process in which reagents, instruments, and systems are intended for the diagnosis of disease or other conditions or for determining the state of health, to cure, mitigate, treat, or prevent disease. This includes reagents, calibrators, control materials, specimen receptacles, software, and related instruments.

The in-vitro diagnostics market is segmented into Enzyme-Linked Immunosorbent Assay (ELISA), Radioimmunoassay (RIA), Rapid tests, Enzyme-Linked Immunospot (Elispot) Assay and others are some of the immunoassay techniques in the IVD market. Basic Metabolic Panel, Electrolyte Panel, liver Panel, Lipid Profile, Renal Profile and Thyroid function panel and specialty chemical tests are some of the clinical chemistry technologies. Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Microarray, Hybridization, DNA Sequencing & Next-Generation Sequencing and others are some of the molecular diagnostics market. Along with these, clinical microbiology, hematology, coagulation and hemostasis and others are the type of the IVD technologies in the market.

Among technologies in in-vitro diagnostics market, immunochemistry techniques accounted for the largest share in 2016 growing at mid range single digit CAGR and molecular diagnostics is expected to grow at high single digit CAGR from 2016-2023.

By application, the in-vitro diagnostics global market is segmented into oncology, diabetes, cardiology, nephrology, transplantation technology, genetic testing, autoimmune diseases, drug testing, infectious diseases and others. Infectious diseases held the largest revenue in 2016 and transplantation diagnostics application is expected to grow at double digit CAGR from 2016-2023.

By product type, the market is segmented into reagents, instruments, software and services. The reagents segment accounted for the largest revenue in 2016, and is expected to grow at mid range single digit CAGR from 2016 to 2023.

By sample type, the market is segmented into blood, urine, saliva and others. The blood segment accounted for the largest revenue in 2016, and is expected to grow at mid range single digit CAGR from 2016 to 2023.

By end-users, the market is segmented into laboratories, hospitals, academic, and home care. The hospitals end user segment accounted for the largest revenue in 2016, home healthcare is fastest growing segment during the forecasting period.

By geography, the market is segmented into North America, Europe, Asia-Pacific and Rest of World. North America holds the largest market share in 2016, followed by Europe and Asia. The APAC regions tend to be an emerging market with an opportunity for growth with a highest CAGR from 2016-2023 and are likely to be a destination of investment for new investors in the in-vitro diagnosis market.

Growing healthcare expenditure in the emerging markets, strong demand for technologically advanced testing methods for disease diagnosis, increasing adaptation of point of care testing, increasing incidences of chronic lifestyle diseases are some of the important driving factors for this market. It is also seen that there is an increase in the number of clinical laboratories with improved infrastructure in many developed countries which could further push the diagnostics market in these regions. However, Lack of proper reimbursement policies in the developing countries and stringent regulatory framework are the main factors hampering the growth of the IVD market.

The in-vitro diagnostics global market is a competitive and all the active players in this market are involved in innovating new and advanced products to maintain their market shares. The key players in the in-vitro diagnostics global market include Abbott Laboratories (U.S.), Becton Dickinson (U.S.), Bio-Rad laboratories (U.S.), BioMerieux  (France), Danaher Corporation (U.S.), Hoffmann-la Roche (Switzerland), Siemens AG (Germany), Carlyle Group (Ortho Clinical Diagnostics) (U.S.), Johnson and Johnson (U.S.), Sysmex Corporation (Japan), ThermoFisher Scientific (U.S.), and Hologic Inc (U.S.).

The report provides an in depth market analysis of the above mentioned segments across the following regions:

• North America

• Europe

• Asia-Pacific

• Rest of the World (RoW)

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKE AWAYS
    • 2.2     REPORT DESCRIPTION
    • 2.3     MARKETS COVERED
    • 2.4     STAKEHOLDERS
    • 2.5     RESEARCH METHODOLOGY
      • 2.5.1     MARKET SIZE ESTIMATION
      • 2.5.2     MARKET BREAKDOWN & DATA TRIANGULATION
      • 2.5.3     SECONDARY SOURCES
      • 2.5.4     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.5.5     PRIMARY SOURCES
      • 2.5.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.5.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     GROWING INCIDENCE OF CHRONIC AND INFECTIOUS DISEASES
        • 3.3.1.2     INCREASING ADOPTION OF POINT-OF-CARE TESTING
        • 3.3.1.3     EMERGENCE OF NEXT GENERATION MOLECULAR DIAGNOSTICS
        • 3.3.1.4     GROWING AWARENESS OF COMPANION DIAGNOSTICS AND PERSONALIZED MEDICINE
        • 3.3.1.5     EMERGENCE OF MINIMALLY INVASIVE AND NON INVASIVE DIAGNOSTICS
        • 3.3.1.6     RISING NUMBER OF CLIA-WAIVED IVD TESTS
      • 3.3.2     RESTRAINTS & THREATS
        • 3.3.2.1     RISING INCIDENCE OF PRODUCT RECALLS
        • 3.3.2.2     LACK OF SKILLED LABORATORY TECHNICIANS IN DEVELOPING NATIONS
        • 3.3.2.3     INADEQUATE REIMBURSEMENT
        • 3.3.2.4     STRINGENT REGULATORY FRAMEWORK
    • 3.4     PORTER’S FIVE FORCE ANALYSIS
      • 3.4.1     THREAT OF NEW ENTRANTS
      • 3.4.2     THREAT OF SUBSTITUTES
      • 3.4.3     BARGAINING POWER OF SUPPLIERS
      • 3.4.4     BARGAINING POWER OF BUYERS
      • 3.4.5     RIVALRY AMONG EXISTING COMPETITORS
    • 3.5     REGULATORY AFFAIRS
    • 3.6     TECHNOLOGICAL ADVANCEMENTS
    • 3.7     FUNDING SCENARIO
    • 3.8     SUPPLY CHAIN ANALYSIS
    • 3.9     MARKET SHARE ANALYSIS BY IN-VITRO DIAGNOSTICS MAJOR PLAYERS
      • 3.9.1     MARKET SHARE ANALYSIS BY IMMUNOASSAY IN-VITRO DIAGNOSTICS MAJOR PLAYERS
      • 3.9.2     MARKET SHARE ANALYSIS BY CLINICAL CHEMISTRY IN-VITRO DIAGNOSTICS MAJOR PLAYERS
      • 3.9.3     MARKET SHARE ANALYSIS BY MOLECULAR DIAGNOSTICS MAJOR PLAYERS
      • 3.9.4     MARKET SHARE ANALYSIS BY CLINICAL MICROBIOLOGY IN-VITRO DIAGNOSTICS MAJOR PLAYERS
      • 3.9.5     MARKET SHARE ANALYSIS BY HEMATOLOGY IN-VITRO DIAGNOSTICS MAJOR PLAYERS
      • 3.9.6     MARKET SHARE ANALYSIS BY COAGULATION AND HEMOSTASIS IN-VITRO DIAGNOSTICS MAJOR PLAYERS
  • 4     IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY TECHNOLOGY
    • 4.1     INTRODUCTION
    • 4.2     IMMUNOCHEMISTRY
      • 4.2.1     ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)
        • 4.2.1.1     CHEMILUMINESCENCE IMMUNOASSAYS (CLIAS)
        • 4.2.1.2     FLUORESCENCE IMMUNOASSAYS (FIAS)
        • 4.2.1.3     COLORIMETRIC IMMUNOASSAYS (CIS)
      • 4.2.2     RADIOIMMUNOASSAY (RIA)
      • 4.2.3     ENZYME-LINKED IMMUNOSPOT (ELISPOT) ASSAY
      • 4.2.4     RAPID TESTS
      • 4.2.5     OTHER IMMUNOASSAY TECHNIQUES
    • 4.3     CLINICAL CHEMISTRY
      • 4.3.1     BASIC METABOLIC PROFILE
      • 4.3.2     ELECTROLYTE PANEL
      • 4.3.3     LIVER PANEL
      • 4.3.4     LIPID PANEL
      • 4.3.5     RENAL PANEL
      • 4.3.6     THYROID FUNCTION PANEL
      • 4.3.7     SPECIALTY CHEMICAL TESTS
    • 4.4     MOLECULAR DIAGNOSTICS
      • 4.4.1     PCR (POLYMERASE CHAIN REACTION)
      • 4.4.2     ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
      • 4.4.3     MICROARRAY
      • 4.4.4     HYBRIDIZATION
      • 4.4.5     DNA SEQUENCING AND NEXT GENERATION SEQUENCING (NGS)
      • 4.4.6     OTHER MDX TECHNOLOGIES
    • 4.5     CLINICAL MICROBIOLOGY
    • 4.6     HEMATOLOGY
    • 4.7     COAGULATION AND HEMOSTASIS
    • 4.8     OTHER IVD TECHNOLOGIES
  • 5     IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY APPLICATION
    • 5.1     INTRODUCTION
    • 5.2     ONCOLOGY
    • 5.3     DIABETES
    • 5.4     INFECTIOUS DISEASES
    • 5.5     GENETIC TESTING
    • 5.6     CARDIOLOGY
    • 5.7     AUTOIMMUNE DISEASES
    • 5.8     DRUG TESTING
    • 5.9     NEPHROLOGY
    • 5.10     TRANSPLANTATION TECHNOLOGY
    • 5.11     OTHERS
  • 6     IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY PRODUCT
    • 6.1     INTRODUCTION
    • 6.2     INSTRUMENTS
    • 6.3     REAGENTS
    • 6.4     SOFTWARE AND SERVICES
  • 7     IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE
    • 7.1     INTRODUCTION
    • 7.2     BLOOD
    • 7.3     SALIVA
    • 7.4     URINE
    • 7.5     OTHERS
  • 8     IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY END USER
    • 8.1     INTRODUCTION
    • 8.2     DIAGNOSTIC LABORATORIES
    • 8.3     HOSPITALS
    • 8.4     ACADEMIC & RESEARCH CENTRES
    • 8.5     HOME CARE
    • 8.6     OTHER END USERS
  • 9     REGIONAL MARKET ANALYSIS
    • 9.1     INTRODUCTION
    • 9.2     NORTH AMERICA
      • 9.2.1     U.S.
      • 9.2.2     OTHERS
    • 9.3     EUROPE
      • 9.3.1     GERMANY
      • 9.3.2     ITALY
      • 9.3.3     FRANCE
      • 9.3.4     OTHERS
    • 9.4     ASIA PACIFIC
      • 9.4.1     INDIA
      • 9.4.2     CHINA
      • 9.4.3     JAPAN
      • 9.4.4     OTHERS
    • 9.5     REST OF THE WORLD
      • 9.5.1     BRAZIL
      • 9.5.2     REST OF LATIN AMERICA
      • 9.5.3     MIDDLE EAST AND OTHERS
  • 10     COMPANY DEVELOPMENTS
    • 10.1     INTRODUCTION
      • 10.1.1     REGULATORY APPROVAL AS A MAJOR GROWTH STRATEGY OF IN-VITRO DIAGNOSTICS MARKET PLAYERS
    • 10.2     APPROVAL
    • 10.3     NEW PRODUCT LAUNCH
    • 10.4     AGREEMENTS, PARTERNER SHIPS, COLLABORATIONS & JOINT VENTURES
    • 10.5     MERGERS AND ACQUISITIONS
    • 10.6     BUSINESS EXPANSION
  • 11     COMPANY PROFILES
    • 11.1     ABBOTT LABORATORIES
      • 11.1.1     OVERVIEW
      • 11.1.2     FINANCIALS
      • 11.1.3     PRODUCT PORTFOLIO
      • 11.1.4     KEY DEVELOPMENTS
      • 11.1.5     BUSINESS STRATEGY
      • 11.1.6     SWOT ANALYSIS
    • 11.2     BECTON DICKINSON AND COMPANY
      • 11.2.1     OVERVIEW
      • 11.2.2     FINANCIALS
      • 11.2.3     PRODUCT PORTFOLIO
      • 11.2.4     KEY DEVELOPMENTS
      • 11.2.5     BUSINESS STRATEGY
      • 11.2.6     SWOT ANALYSIS
    • 11.3     BIOMERIEUX
      • 11.3.1     OVERVIEW
      • 11.3.2     FINANCIALS
      • 11.3.3     PRODUCT PORTFOLIO
      • 11.3.4     KEY DEVELOPMENTS
      • 11.3.5     BUSINESS STRATEGY
      • 11.3.6     SWOT ANALYSIS
    • 11.4     BIO-RAD LABORATORIES
      • 11.4.1     OVERVIEW
      • 11.4.2     FINANCIALS
      • 11.4.3     PRODUCT PORTFOLIO
      • 11.4.4     KEY DEVELOPMENTS
      • 11.4.5     BUSINESS STRATEGY
      • 11.4.6     SWOT ANALYSIS
    • 11.5     CARLYLE GROUP (ORTHO CLINICAL DIAGNOSTICS)
      • 11.5.1     OVERVIEW
      • 11.5.2     FINANCIALS
      • 11.5.3     PRODUCT PORTFOLIO
      • 11.5.4     KEY DEVELOPMENTS
      • 11.5.5     BUSINESS STRATEGY
      • 11.5.6     SWOT ANALYSIS
    • 11.6     DANAHER CORPORATION
      • 11.6.1     OVERVIEW
      • 11.6.2     FINANCIALS
      • 11.6.3     PRODUCT PORTFOLIO
      • 11.6.4     KEY DEVELOPMENTS
      • 11.6.5     BUSINESS STRATEGY
      • 11.6.6     SWOT ANALYSIS
    • 11.7     JOHNSON & JOHNSON
      • 11.7.1     OVERVIEW
      • 11.7.2     FINANCIALS
      • 11.7.3     PRODUCT PORTFOLIO
      • 11.7.4     KEY DEVELOPMENTS
      • 11.7.5     BUSINESS STRATEGY
      • 11.7.6     SWOT ANALYSIS
    • 11.8     ROCHE HOLDINGS AG
      • 11.8.1     OVERVIEW
      • 11.8.2     FINANCIALS
      • 11.8.3     PRODUCT PORTFOLIO
      • 11.8.4     KEY DEVELOPMENTS
      • 11.8.5     BUSINESS STRATEGY
      • 11.8.6     SWOT ANALYSIS
    • 11.9     SIEMENS AG
      • 11.9.1     OVERVIEW
      • 11.9.2     FINANCIALS
      • 11.9.3     PRODUCT PORTFOLIO
      • 11.9.4     KEY DEVELOPMENTS
      • 11.9.5     BUSINESS STRATEGY
      • 11.9.6     SWOT ANALYSIS
    • 11.10     SYSMEX CORPORATION (SYSMEX INOSTICS)
      • 11.10.1     OVERVIEW
      • 11.10.2     FINANCIALS
      • 11.10.3     PRODUCT DESCRIPTION
      • 11.10.4     KEY DEVELOPMENTS
      • 11.10.5     BUSINESS STRATEGY
      • 11.10.6     SWOT ANALYSIS
    • 11.11     THERMOFISHER SCIENTIFIC INC.
      • 11.11.1     OVERVIEW
      • 11.11.2     FINANCIALS
      • 11.11.3     PRODUCT PORTFOLIO
      • 11.11.4     KEY DEVELOPMENTS
      • 11.11.5     BUSINESS STRATEGY
      • 11.11.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 2     IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY TECHNOLOGY (2015-2023) ($MN)
      • TABLE 3     IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY APPLICATIONS (2015-2023) ($MN)
      • TABLE 4     IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY PRODUCT (2015-2023) ($MN)
      • TABLE 5     IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY SAMPLE TYPES, (2015-2023) ($MN)
      • TABLE 6     IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY END-USERS, (2015-2023) ($MN)
      • TABLE 7     IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY TECHNOLOGY (2015-2023) ($MN)
      • TABLE 8     IMMUNOCHEMISTRY IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 9     IMMUNOCHEMISTRY IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY TYPE (2015-2023) ($MN)
      • TABLE 10     ENZYME-LINKED IMMUNOSORBENT ASSAY TECHNOLOGY OF IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 11     RADIOIMMUNOASSAY (RIA) IN IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY REGION (2015-2023) ($MN)
      • TABLE 12     ENZYME-LINKED IMMUNOSPOT (ELISPOT) ASSAY IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY REGION (2015-2023) ($MN)
      • TABLE 13     RAPID TESTS IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY REGION (2015-2023) ($MN)
      • TABLE 14     OTHER IMMUNOASSAYS IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY REGION (2015-2023) ($MN)
      • TABLE 15     CLINICAL CHEMISTRY IN IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY REGION (2015-2023) ($MN)
      • TABLE 16     CLINICAL CHEMISTRY IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY TYPE (2015-2023) ($MN)
      • TABLE 17     BASIC METABOLIC PROFILE IN IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 18     ELECTROLYTE PANEL IN IN-VITRO DIAGNOSTICS REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 19     LIVER PANEL IN IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 20     LIPID PANEL IN IN-VITRO DIAGNOSTIC GLOBAL MARKET, BY REGION (2015-2023) ($MN)
      • TABLE 21     RENAL PROFILE IN IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY REGION (2015-2023) ($MN)
      • TABLE 22     THYROID FUNCTION PANEL IN INVITRO DIAGNOSTICS GLOBAL MARKET, BY REGION (2015-2023) ($MN)
      • TABLE 23     SPECIALTY CHEMICAL TEST IN IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY REGION(2015-2023) ($MN)
      • TABLE 24     MOLECULAR DIAGNOSTICS IN IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 25     MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TYPES, (2015-2023) ($MN)
      • TABLE 26     PCR TECHNIQUE IN IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 27     INAAT TECHNIQUE IN IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 28     MICROARRAY TECHNIQUE IN IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 29     HYBRIDIZATION TECHNIQUE IN IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 30     DNA SEQUENCING AND NGS TECHNIQUE IN IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 31     OTHER MDX TECHNIQUES IN IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 32     CLINICAL MICROBIOLOGY TECHNIQUE IN IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 33     HEMATOLOGY TECHNIQUE IN IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 34     COAGULATION AND HEMOSTASIS TECHNIQUE IN IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 35     OTHER IVD TECHNIQUES IN IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 36     IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY APPLICATIONS (2015-2023) ($MN)
      • TABLE 37     ONCOLOGY IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 38     DIABETES IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 39     INFECTIOUS DISEASE IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 40     GENETIC TESTING IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 41     CARDIOLOGY IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 42     AUTOIMMUNE DISEASES IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 43     DRUG TESTING IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 44     NEPHROLOGY IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 45     TRANSPLANTATION TECHNOLOGY IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 46     OTHER APPLICATIONS IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 47     IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY PRODUCT TYPE (2015-2023) ($MN)
      • TABLE 48     IN-VITRO DIAGNOSTICS INSTRUMENTS GLOBAL MARKET, BY REGION (2015-2023) ($MN)
      • TABLE 49     IN-VITRO DIAGNOSTICS REAGENTS GLOBAL MARKET, BY REGION, (2015-2023) ($MN)
      • TABLE 50     IN-VITRO DIAGNOSTICS SOFTWARE AND SERVICES GLOBAL MARKET, BY REGION (2015-2023) ($MN)
      • TABLE 51     IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY SAMPLE TYPE (2015-2023) ($MN)
      • TABLE 52     BLOOD SAMPLE TYPE IN IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 53     SALIVA SAMPLE TYPE IN IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 54     URINE SAMPLE TYPE IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 55     OTHER SAMPLE TYPE IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 56     IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY END-USERS, (2015-2023) ($MN)
      • TABLE 57     DIAGNOSTIC LABORATORIES IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 58     HOSPITALS IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 59     ACEDEMICS AND RESEARCH CENTRES IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 60     HOME CARE IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 61     OTHER END USERS IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 62     IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 63     NORTH AMERICAN IN-VITRO DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2015-2023) ($MN)
      • TABLE 64     NORTH AMERICAN IN-VITRO DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2015-2023) ($MN)
      • TABLE 65     NORTH AMERICAN IN-VITRO DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2015-2023) ($MN)
      • TABLE 66     NORTH AMERICAN IN-VITRO DIAGNOSTICS MARKET REVENUE, BY SAMPLE TYPE, (2015-2023) ($MN)
      • TABLE 67     NORTH AMERICAN IN-VITRO DIAGNOSTICS MARKET REVENUE, BY END USERS, (2015-2023) ($MN)
      • TABLE 68     NORTH AMERICAN IN-VITRO DIAGNOSTICS MARKET REVENUE, BY COUNTRY, (2015-2023) ($MN)
      • TABLE 69     EUROPE IN-VITRO DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2015-2023) ($MN)
      • TABLE 70     EUROPE IN-VITRO DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2015-2023) ($MN)
      • TABLE 71     EUROPE IN-VITRO DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2015-2023) ($MN)
      • TABLE 72     EUROPE IN-VITRO DIAGNOSTICS MARKET REVENUE, BY SAMPLE TYPE, (2015-2023) ($MN)
      • TABLE 73     EUROPE IN-VITRO DIAGNOSTICS MARKET REVENUE, BY END USERS, (2015-2023) ($MN)
      • TABLE 74     EUROPE IN-VITRO DIAGNOSTICS MARKET REVENUE, BY COUNTRY, (2015-2023) ($MN)
      • TABLE 75     ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2015-2023) ($MN)
      • TABLE 76     ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2015-2023) ($MN)
      • TABLE 77     ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2015-2023) ($MN)
      • TABLE 78     ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET REVENUE, BY SAMPLE TYPE, (2015-2023) ($MN)
      • TABLE 79     ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET REVENUE, BY END USERS, (2015-2023) ($MN)
      • TABLE 80     ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET REVENUE, BY COUNTRY, (2015-2023) ($MN)
      • TABLE 81     ROW IN-VITRO DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2015-2023) ($MN)
      • TABLE 82     ROW IN-VITRO DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2015-2023) ($MN)
      • TABLE 83     ROW IN-VITRO DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2015-2023) ($MN)
      • TABLE 84     ROW IN-VITRO DIAGNOSTICS MARKET REVENUE, BY SAMPLE TYPE, (2015-2023) ($MN)
      • TABLE 85     ROW IN-VITRO DIAGNOSTICS MARKET REVENUE, BY END USERS, (2015-2023) ($MN)
      • TABLE 86     ROW IN-VITRO DIAGNOSTICS MARKET REVENUE, BY COUNTRY, (2015-2023) ($MN)
      • TABLE 87     APPROVALS (2015-2016)
      • TABLE 88     NEW PRODUCT LAUNCH (2015-2016)
      • TABLE 89     AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (2015-2016)
      • TABLE 90     MERGERS AND ACQUITIONS (2015-2016)
      • TABLE 91     BUSINESS EXPANSION (2015-2016)
      • TABLE 92     ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 93     ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 94     ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 95     BECTON DICKINSON AND COMPANY: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 96     BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 97     BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY LIFE SCIENCE SEGMENTS, (2014-2016) ($MN)
      • TABLE 98     BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 99     BIOMERIEUX: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 100     BIOMERIEUX: TOTAL REVENUE,BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 101     BIOMEREIUX: TOTAL REVENUE, BY CLINICAL SEGMENTS, (2014-2016) ($MN)
      • TABLE 102     BIOMEREIUX: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016*) ($MN)
      • TABLE 103     BIO-RAD LABORATORIES: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
      • TABLE 104     BIO-RAD LABORATORIES: TOTAL REVENUE BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 105     BIO-RAD LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 106     DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 107     DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 108     DANAHER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 109     JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 110     JOHNSON & JOHNSON: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 111     JOHNSON & JOHNSON: TOTAL REVENUE, BY MEDICAL DEVICE SEGMENTS, (2014-2016) ($MN)
      • TABLE 112     JOHNSON & JOHNSON: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 113     ROCHE HOLDINGS AG: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 114     ROCHE HOLDINGS AG: TOTAL REVENUE BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 115     ROCHE HOLDINGS AG: DIAGNOSTICS REVENUE BY TYPES, (2014-2016) ($MN)
      • TABLE 116     ROCHE HOLDINGS AG: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 117     SIEMENS AG: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 118     SIEMENS AG: TOTAL REVENUE, BY SEGMENT, (2014-2016) ($MN)
      • TABLE 119     SIEMENS AG : TOTAL REVENUE, BY GEOGRAPHY (2014-2016) ($MN)
      • TABLE 120     SYSMEX CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 121     SYSMEX CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 122     SYSMEX CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 123     SYSMEX CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2014-2016) ($MN)
      • TABLE 124     THERMOFISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 125     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 126     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)

      LIST OF FIGURES

      • FIGURE 1     IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY GEOGRAPHY (2015-2023)
      • FIGURE 2     RESEARCH METHODOLOGY: IN-VITRO DIAGNOTRICS GLOBAL MARKET
      • FIGURE 3     IN-VITRO DIAGNOSTIC GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     IN-VITRO DIAGNOSTICS GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     IN-VITRO DIAGNOSTICS GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
      • FIGURE 6     IVD MARKET: MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     IN-VITRO DIAGNOSTICS GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 9     IN-VITRO DIAGNOSTICS GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 10     IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2016
      • FIGURE 11     IMMUNOASSAY IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2016
      • FIGURE 12     CLINICAL CHEMISTRY IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2016
      • FIGURE 13     MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2016
      • FIGURE 14     CLINICAL MICROBIOLOGY IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2016
      • FIGURE 15     HEMATOLOGY IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2016
      • FIGURE 16     COAGULATION AND HEMOSTASIS IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2016
      • FIGURE 17     IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNOLOGY, (2016 V’S 2023)
      • FIGURE 18     IMMUNOCHEMISTRY IN-VITRO DIAGNOSTICS MARKET SHARE, BY TYPE (2016 V’S 2023) (%)
      • FIGURE 19     CLINICAL CHEMISTRY IN-VITRO DIAGNOSTICS MARKET SHARE, BY TYPE (2016 V’S 2023) (%)
      • FIGURE 20     MOLECULAR DIAGNOSTICS IN-VITRO DIAGNOSTICS MARKET SHARE, BY TYPE (2016 V’S 2023) (%)
      • FIGURE 21     IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY APPLICATIONS (2016 V’S 2023) (%)
      • FIGURE 22     IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY PRODUCTS, (2015-2023) ($MN)
      • FIGURE 23     IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY SAMPLE TYPE, 2016 ($MN)
      • FIGURE 24     IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USERS (2016 V’S 2023) ($MN)
      • FIGURE 25     IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN), CAGR (%)
      • FIGURE 26     OUTLOOK OF NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY (2016 V’S 2023) ($MN)
      • FIGURE 27     OUTLOOK OF NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 28     OUTLOOK OF NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE, PRODUCTS AND END USERS (2016 V’S 2023) ($MN)
      • FIGURE 29     OUTLOOK OF U.S. IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, APPLICATION (2016 V’S 2023) ($MN)
      • FIGURE 30     OUTLOOK OF U.S. IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE, PRODUCTS AND END USERS (2016 V’S 2023) ($MN)
      • FIGURE 31     OUTLOOK OF OTHER NORTH AMERICAN IN-VITRO DIAGNOSTICS MARKET, BY APPLICATIONS, TECHNIQUES (2016 V’S 2023) ($MN)
      • FIGURE 32     OUTLOOK OF OTHER NORTH AMERICAN IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE, PRODUCTS AND END USERS (2016 V’S 2023) ($MN)
      • FIGURE 33     OUTLOOK OF EUROPE IN-VITRO DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2016 V’S 2023) ($MN)
      • FIGURE 34     OUTLOOK OF EUROPE IN-VITRO DIAGNOSTICS MARKET SHARE, BY APPLICATION (2016 V’S 2023) ($MN)
      • FIGURE 35     OUTLOOK OF EUROPE IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE, PRODUCTS AND END USERS (2016 V’S 2023) ($MN)
      • FIGURE 36     OUTLOOK OF GERMANY IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, & APPLICATION (2016 V’S 2023) ($MN)
      • FIGURE 37     OUTLOOK OF GERMANY IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE, PRODUCTS & END USERS (2016 V’S 2023) ($MN)
      • FIGURE 38     OUTLOOK OF ITALY IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, APPLICATION (2016 V’S 2023) ($MN)
      • FIGURE 39     OUTLOOK OF ITALY IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE, PRODUCTS & END USERS (2016 V’S 2023) ($MN)
      • FIGURE 40     OUTLOOK OF FRANCE IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, & APPLICATION (2016 V’S 2023) ($MN)
      • FIGURE 41     OUTLOOK OF FRANCE IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE, PRODUCTS & END USERS (2016 V’S 2023) ($MN)
      • FIGURE 42     OUTLOOK OF OTHER EUROPEAN IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, & APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 43     OUTLOOK OF OTHER EUROPEAN IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE, PRODUCTS & END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 44     OUTLOOK OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2016 V’S 2023) ($MN)
      • FIGURE 45     OUTLOOK OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SHARE, BY APPLICATION (2016 V’S 2023) ($MN)
      • FIGURE 46     OUTLOOK OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE, PRODUCTS & END USERS (2016 V’S 2023) ($MN)
      • FIGURE 47     OUTLOOK OF INDIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY & APPLICATION (2016 V’S 2023) ($MN)
      • FIGURE 48     OUTLOOK OF INDIA IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE, PRODUCTS & END USERS (2016 V’S 2023) ($MN)
      • FIGURE 49     OUTLOOK OF CHINA IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, & APPLICATION (2016 V’S 2023) ($MN)
      • FIGURE 50     OUTLOOK OF CHINA IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE, PRODUCTS & END USERS (2016 V’S 2023) ($MN)
      • FIGURE 51     OUTLOOK OF JAPAN IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, & APPLICATION (2016 V’S 2023) ($MN)
      • FIGURE 52     OUTLOOK OF JAPAN IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE, PRODUCTS & END USERS (2016 V’S 2023) ($MN)
      • FIGURE 53     OUTLOOK OF OTHER ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, APPLICATIONS & END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 54     OUTLOOK OF OTHER ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE, PRODUCTS & END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 55     OUTLOOK OF ROW IN-VITRO DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2016 V’S 2023) ($MN)
      • FIGURE 56     OUTLOOK OF ROW IN-VITRO DIAGNOSTICS MARKET SHARE, BY APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 57     OUTLOOK OF ROW IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE, PRODUCTS & END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 58     OUTLOOK OF BRAZIL IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, & APPLICATION (2016 V’S 2023) ($MN)
      • FIGURE 59     OUTLOOK OF BRAZIL IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE, PRODUCTS & END USERS (2016 V’S 2023) ($MN)
      • FIGURE 60     OUTLOOK OF REST OF LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, & APPLICATION (2016 V’S 2023) ($MN)
      • FIGURE 61     OUTLOOK OF REST OF LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE, PRODUCTS & END USERS (2016 V’S 2023) ($MN)
      • FIGURE 62     OUTLOOK OF MIDDLE EAST AND OTHERS IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, & APPLICATION (2016 V’S 2023) ($MN)
      • FIGURE 63     OUTLOOK OF MIDDLE EAST AND OTHERS IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE, PRODUCTS & END USERS (2016 V’S 2023) ($MN)
      • FIGURE 64     KEY GROWTH STRATEGIES (2015-2016)
      • FIGURE 65     SWOT: ABBOTT LABORATORIES
      • FIGURE 66     SWOT: BECTON DICKINSON AND COMPANY
      • FIGURE 67     SWOT: BIOMEREIUX
      • FIGURE 68     SWOT: BIO-RAD LABORATORIES
      • FIGURE 69     SWOT: CARLYLE GROUP (ORTHO CLINICAL DIAGNOSTIC)
      • FIGURE 70     SWOT: DANAHER CORPORATION
      • FIGURE 71     SWOT: JOHNSON & JOHNSON
      • FIGURE 72     SWOT: HOFFMANN LA ROCHE
      • FIGURE 73     SWOT: SIEMENS AG
      • FIGURE 74     SWOT: SYSMEX CORPORATION
      • FIGURE 75     SWOT:THERMOFISHER SCIENTIFIC

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     A. MENARINI DIAGNOSTICS S.R.L
      • 2     AARKRAY INC
      • 3     AB2BIO
      • 4     ABACUS DIAGNOSTICA
      • 5     ABAXIS EUROPE GMBH
      • 6     ABBOTT LABORATORIES
      • 7     ABCAM
      • 8     ABINGDON HEALTH
      • 9     ABIONIC SA
      • 10     ACCRIVA DIAGNOSTICS
      • 11     ACCUREX BIOMEDICAL
      • 12     ACCUTECH INC
      • 13     ACHIRA LABS
      • 14     ACON LABORATORIES, INC
      • 15     ADALTIS
      • 16     ADNAGEN AG
      • 17     ADVIN BIOTECH
      • 18     AGAPPE
      • 19     AGENA BIOSCIENCES
      • 20     AGILENT TECHNOLOGIES
      • 21     ALFA SCIENTIFIC DESIGNS
      • 22     ALLIANCE INTERNATIONAL 
      • 23     ALPCO
      • 24     ALPHA SCIENTIFIC
      • 25     AMERICAN BIOMEDICA
      • 26     ANALYTIK JENA AG
      • 27     ANI BIOTECH OY,
      • 28     ANTECH DIAGNOSTICS
      • 29     AQUILA DIAGNOSTIC SYSTEMS INC.
      • 30     ARBOR VITA CORPORATION
      • 31     ARCHER DX
      • 32     ARQUER DIAGNOSTICS
      • 33     ARUP LABORATORIES
      • 34     ASCENSIA DIABETES CARE HOLDINGS AG
      • 35     ASTELLAS PHARMA
      • 36     ASURE QUALITY
      • 37     ATLAS MEDICAL
      • 38     ATOMO DIAGNOSTICS
      • 39     AURELIUM BIOPHARMA INC
      • 40     AUSDIAGNOSTICS PVT LTD
      • 41     AUTOGENOMICS
      • 42     BAYER AG
      • 43     BEACON BIOMEDICAL
      • 44     BECTON DICKINSON
      • 45     BERRY GENOMICS CO. LTD
      • 46     BEURER
      • 47     BGI
      • 48     BIO-AMD
      • 49     BIOAZURE TECHNOLOGIES
      • 50     BIOCAT GMBH
      • 51     BIOFORTUNA LTD
      • 52     BIOGAZELLE
      • 53     BIOKIT S.A.
      • 54     BIOLIGHT LIFE SCIENCES
      • 55     BIOLYTICAL LABORATORIES INC.
      • 56     BIOMEDICA DIAGNOSTICS
      • 57     BIOMERIEUX
      • 58     BIOPHORE
      • 59     BIO-RAD LABORATORIES
      • 60     BIOSEARCH TECHNOLOGIES
      • 61     BIOVISION
      • 62     BLUEJAY DIAGNOSTICS, INC.
      • 63     BREMED
      • 64     BRUKER CORPORATION
      • 65     BTNX INC
      • 66     CAREDX
      • 67     CAREMATIX INC.
      • 68     CAREWELL BIOTECH
      • 69     CARIS LIFE SCIENCES
      • 70     CARLYLE GROUP (ORTHO CLINICAL DIAGNOSTICS)
      • 71     CEPHEID INC
      • 72     CHEMBIO DIAGNOSTIC SYSTEMS, INC.
      • 73     CHERRY BIOTECH
      • 74     CHRONIX BIOMEDICAL
      • 75     CHURCH & DWIGHT CO., INC.,
      • 76     COELIAC AUSTRALIA
      • 77     CONVERGENT TECHNOLOGIES
      • 78     CORE DIAGNOSTICS
      • 79     CORGENIX
      • 80     CURIOSITY DIAGNOSTICS
      • 81     CYTOTEST
      • 82     CYTYC
      • 83     DAAN GENE
      • 84     DAKTARI DIAGNOSTICS
      • 85     DANAHER CORPORATION
      • 86     DARIO
      • 87     DCC PLC., 
      • 88     DEMEDITEC DIAGNOSTICS
      • 89     DEXCOM INC.
      • 90     DIABETOMICS
      • 91     DIACARTA
      • 92     DIAGNOSTIC BIOSYSTEMS
      • 93     DIAGNOSTICS BIOCHEM CANADA INC.
      • 94     DIAN DIAGNOSTICS
      • 95     DIASORIN
      • 96     DIASYS DIAGNOSTIC SYSTEMS GMBH
      • 97     DIATRON
      • 98     DIAZYME LABORATORIES
      • 99     DIGENE CORPORATION
      • 100     DNAGENOTEK
      • 101     DRUCKER DIAGNOSTICS
      • 102     D-TEK S.A.
      • 103     ECOLI LTD
      • 104     EKF DIAGNOSTICS
      • 105     ELITECH GROUP
      • 106     EMSIG GMBH CO.
      • 107     ENIGMA DIAGNOSTICS
      • 108     ENTERIX, INC
      • 109     ENZO LIFE SCIENCES
      • 110     EPITOPE DIAGNOSTICS INC,
      • 111     ERBA MANNHEIM GMBH
      • 112     EURO-DIAGNOSTICA AB
      • 113     EUROMEDIX POC NV/SA
      • 114     EXACT SCIENCES CORPORATION
      • 115     EXOSOME DIAGNOSTICS
      • 116     FANNIN
      • 117     FIRST DIAGNOSTICS CORPORATION
      • 118     FLUIDIGM CORPORATION
      • 119     FOSUN DIAGNOSTICS
      • 120     FUJIREBIO INC
      • 121     GE HEALTHCARE
      • 122     GENETIC SIGNATURES
      • 123     GENMARK DIAGNOSTICS, INC
      • 124     GLYSENS, INC.
      • 125     GLYSURE
      • 126     GRAIL
      • 127     GREINER DIAGNOSTIC GMBH
      • 128     GRIFOLS
      • 129     GUARDANT HEALTH
      • 130     HANGZHOU SEJOY ELECTRONICS & INSTRUMENTS 
      • 131     HEALTHIANS
      • 132     HELENA LABORATORIES
      • 133     HEMOSURE INC.,
      • 134     HIBERGENE DIAGNOSTICS
      • 135     HITACHI
      • 136     HOFFMANN-LA ROCHE
      • 137     HOLOGIC INC
      • 138     HORIBA
      • 139     HTG MOLECULAR DIAGNOSTICS INC.
      • 140     HUMOR DIAGNOSTICA
      • 141     HYCEL
      • 142     IGENETIC DIAGNOSTICS PVT. LTD.
      • 143     IHEALTH LABS INC.
      • 144     ILLUMINA
      • 145     IME-DC GMBH
      • 146     IMMUCOR INC
      • 147     IMMUNO PTY LTD
      • 148     IMMUNOSPOT
      • 149     IN4 TECHNOLOGY CORP
      • 150     INBIOS
      • 151     INGENETIX
      • 152     INIVATA LTD
      • 153     INNOGENETICS
      • 154     INOVA DIAGNOSTICS INC.
      • 155     INSILIXA, INC
      • 156     INSTRUMENTATION LABORATORY
      • 157     INTEGRATED DIAGNOSTICS
      • 158     INTEGRITY APPLICATIONS INC.
      • 159     INTERNATIONAL BIOMEDICAL
      • 160     INTERNATIONAL TECHNIDYNE CORPORATION
      • 161     IONICONANALYTIK GMBH
      • 162     J MITRA & CO. PVT. LTD
      • 163     JANT PHARMACAL CORPORATION
      • 164     JOHNSON AND JOHNSON
      • 165     JP BIOGEN DIAGNOSTICS LTD
      • 166     KAMINENI LIFE SCIENCE
      • 167     KMC SYSTEMS
      • 168     KOROGLU MEDICAL DEVICES LTD
      • 169     LABORATORY CORP. OF AMERICA HOLDINGS
      • 170     LABSYSTEMS DIAGNOSTICS OY
      • 171     LABTICIAN OPHTHALMICS, INC
      • 172     LAMBDA SOLUTIONS INC
      • 173     LIFEASSAYS AB
      • 174     LIFECODEXX AG
      • 175     LINKAGE BIOSCIENCES
      • 176     LUCIGEN
      • 177     LUMINEX CORPORATION
      • 178     MABTECH
      • 179     MACCURA BIOTECHNOLOGY LTD
      • 180     MAST GROUP
      • 181     MBIO DIAGNOSTICS, INC
      • 182     MEDGENOME
      • 183     MEDIAN DIAGNOSTICS
      • 184     MEDICA CORPORATION
      • 185     MEDICAL AND BIOLOGICAL LABORATORIES
      • 186     MEDICAL INNOVATION VENTURES
      • 187     MEDISPEC
      • 188     MEDIWISE
      • 189     MEDMIRA
      • 190     MEDTRONIC PLC
      • 191     MEMED
      • 192     MENARINI DIAGNOSTICS
      • 193     MERCK KGAA
      • 194     MERIDIAN BIOSCIENCE, INC,
      • 195     METABOLOMIC DIAGNOSTICS
      • 196     MIACOM DIAGNOSTICS GMBH
      • 197     MICROPOINT BIOSCIENCES LTD
      • 198     MINDRAY MEDICAL INTERNATIONAL LIMITED
      • 199     MOBIDIAG OY
      • 200     MOLBIO DIAGNOSTICS PVT LTD
      • 201     MYRIAD GENETICS
      • 202     NANOENTEK
      • 203     NANOREPRO
      • 204     NANOSPEED DIAGNOSTICS
      • 205     NATERA
      • 206     NEMAURA MEDICAL
      • 207     NEW ZEALAND DIAGNOSTICS GROUP LTD
      • 208     NGAIO DIAGNOSTICS
      • 209     NIHON KOHDEN CORPORATION
      • 210     NIPRO DIAGNOSTICS
      • 211     NOVA BIOMEDICAL CORPORATION
      • 212     NOVAMAX
      • 213     NOVAMED LTD
      • 214     NOVARTIS
      • 215     NOWDIAGNOSTICS
      • 216     OASIS DIAGNOSTICS
      • 217     OMEGA DIAGNOSTICS
      • 218     OMNICA CORPORATION
      • 219     ONCOGENESIS
      • 220     OPERON BIOTECH & HEALTHCARE
      • 221     OPERON S.A.
      • 222     OPKO DIAGNOSTICS
      • 223     OPTHALMIC INSTRUMENT COMPANY
      • 224     OPTIGENE
      • 225     ORAL DNA LABS
      • 226     ORASURE TECHNOLOGIES
      • 227     OVAGENE ONCOLOGY
      • 228     PACIFIC EDGE LTD
      • 229     PARADIGM DIAGNOSTICS
      • 230     PATHWAY GENOMICS
      • 231     PERKIN ELMER INC
      • 232     PERLONG MEDICAL
      • 233     PERSONAL GENOME DIAGNOSTICS
      • 234     PHOENIX MEDCARE
      • 235     PICTOR LIMITED
      • 236     POC MEDICAL SYSTEMS, INC.,
      • 237     POLYMER TECHNOLOGY SYSTEMS INC
      • 238     PREMIER MEDICAL CORPORATION LTD.
      • 239     PRESTIGE BRANDS HOLDINGS, INC.,
      • 240     PROBE SCIENTIFIC
      • 241     PROMEGA CORPORATION
      • 242     PRONTO DIAGNOSTICS
      • 243     PROTAGEN DIAGNOSTICS
      • 244     PTS DIAGNOSTICS
      • 245     QUANTUMDX
      • 246     QUEST DIAGNOSTICS
      • 247     QUIDEL CORPORATION
      • 248     R&D SYSTEMS
      • 249     R&D SYSTEMS
      • 250     RAIN DANCE TECHNOLOGIES (U.S.)
      • 251     RANDOX LABORATORIES LTD
      • 252     RESPONSE BIOMEDICAL
      • 253     ROSETTA GENOMICS
      • 254     RPS DIAGNOSTICS
      • 255     SAMSUNG GROUP
      • 256     SANOFI
      • 257     SAVYON DIAGNOSTICS
      • 258     SENSEONICS
      • 259     SENTINEL DIAGNOSTICS
      • 260     SEQUENOM LABORATORIES
      • 261     SEQUENTA INC.
      • 262     SERACARE LIFE SCIENCES
      • 263     SHANGHAI KEHUA BIO-ENGINEERING CO. LTD.
      • 264     SHENZEN HYDE MEDICAL EQUIPMENT
      • 265     SHIMADZU CORP
      • 266     SIEMENS AG
      • 267     SIENNA CANCER DIAGNOSTICS
      • 268     SIGTUPLE
      • 269     SIMPLE DIAGNOSTICS
      • 270     SISCAPA ASSAY TECHNOLOGIES
      • 271     SKANNEX AS
      • 272     SOLGENT
      • 273     SOMAGEN DIAGNOSTICS
      • 274     SORRENTO THERAPEUTICS
      • 275     SPAN DIAGNOSTICS
      • 276     SUGENTECH INC. 
      • 277     SWISS PRECISION DIAGNOSTICS GMBH
      • 278     SYSMEX CORPORATION
      • 279     TAI DIAGNOSTICS
      • 280     TB BIOSCIENCES, INC
      • 281     TEL-ARRAY
      • 282     THERADIAG
      • 283     THERMOFISHER SCIENTIFIC
      • 284     TOSHIBA
      • 285     TOSOH BIOSCIENCE
      • 286     TRANSASIA BIOMEDICALS
      • 287     TRANSGENOMICS INC.
      • 288     TRIVITRON HEALTHCARE
      • 289     TROVAGENE
      • 290     TULIP DIAGNOSTICS
      • 291     TWIST DIAGNOSTICS
      • 292     UNIVERSAL BIOSENSORS
      • 293     USTAR BIOTECHNOLOGIES
      • 294     VELA DIAGNOSTICS
      • 295     VITRO MOLECULAR LABORATORIES
      • 296     WAKO DIAGNOSTIC
      • 297     WATERS CORPORATION
      • 298     WERFENLIFE
      • 299     WIKKON MEDICAL
      • 300     ZBX CORPORATION
      • 301     ZEUS SCIENTIFIC
      • 302     ZYMORESEARCH